FDA Oversight Of DTC Ads Will Be Examined By HHS Inspector General
This article was originally published in The Pink Sheet Daily
Executive Summary
The Inspector General will determine the effectiveness of FDA procedures for monitoring DTC ads and what actions are taken against companies with false and misleading ads, the IG’s fiscal 2005 work plan says. FDA’s handling of off-label drug promotions will also be studied.
You may also be interested in...
New Labeling Rule Will Require Rx Warnings To Appear At Beginning Of DTC Ads
The proposed physician labeling rule will by published by the end of November, FDA Acting Commissioner Crawford says. The rule is designed to provide more useful information to physicians and patients.
New Labeling Rule Will Require Rx Warnings To Appear At Beginning Of DTC Ads
The proposed physician labeling rule will by published by the end of November, FDA Acting Commissioner Crawford says. The rule is designed to provide more useful information to physicians and patients.
Medicare, Medicaid Rx Price Reporting Are IG Review Priorities For 2005
The HHS Inspector General will conduct several reviews related to drug manufacturers' price reporting for Medicare and Medicaid, IG's fiscal 2005 work plan says